⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30779745 | 1.00 | — | — | |
| SCHEMBL995983 | 0.82 | SOS2 (0.50) | — | |
| SCHEMBL14733148 | 0.80 | NOS1 (0.39) | — | |
| SCHEMBL769270 | 0.76 | — | — | |
| SCHEMBL9220648 | 0.75 | CTSS (0.55) | — | |
| SCHEMBL29988787 | 0.75 | CTSS (0.55) | — | |
| SCHEMBL1771966 | 0.73 | CTSS (0.53) | — | |
| SCHEMBL17039219 | 0.73 | NOS3 (0.46) | — | |
| SCHEMBL64599 | 0.73 | — | — | |
| SCHEMBL12300275 | 0.71 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 301 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102231984-A | Hematopoietic protection against chemotherapeutic compounds using selective cyclin dependent kinase 4/6 inhibitors | UNIV NORTH CAROLINA | 2011-11-02 | — | — | CN | claimed |
| CN-102231983-A | Hematopoietic protection against ionizing radiation using selective cyclin-dependent kinase 4/6 inhibitors | UNIV NORTH CAROLINA | 2011-11-02 | — | — | CN | claimed |
| EP-4701783-A1 | PHOSPHINE-IMINO-QUINOLINE AND RELATED LIGANDS FOR USE IN ETHYLENE OLIGOMERIZATION PROCESSES | Chevron Phillips Chemical Company LP (US) | 2026-03-04 | — | — | EP | disclosed |
| EP-4701782-A1 | CATALYST SYSTEM AND ETHYLENE OLIGOMERIZATION PROCESS FOR THE PREPARATION OF LINEAR ALPHA OLEFINS | Chevron Phillips Chemical Company LP (US) | 2026-03-04 | — | — | EP | disclosed |
| CN-121591700-A | Synthesis method of isopropyl omega-nimidab | 沈阳药科大学 | 2026-03-03 | — | — | CN | disclosed |
| US-12552777-B2 | Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof | ENANTA PHARMACEUTICALS, INC. (US) | 2026-02-17 | — | — | US | disclosed |
| WO-2025226545-A1 | MODULATORS OF MITOCHONDRIAL DNA REPLICATION | PRETZEL THERAPEUTICS, INC. (US) | 2025-10-30 | — | — | WO | disclosed |
| WO-2025215121-A1 | HEDGEHOG ACYLTRANSFERASE INHIBITORS | IMPERIAL COLLEGE INNOVATIONS LIMITED (GB) | 2025-10-16 | — | — | WO | disclosed |
| US-12441724-B2 | Inhibitors of plasma kallikrein and uses thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2025-10-14 | — | — | US | disclosed |
| EP-4615839-A1 | INHIBITORS OF PROTEIN TYROSINE PHOSPHATASE, COMPOSITIONS, AND METHODS OF USE | Bristol-Myers Squibb Company (US) | 2025-09-17 | — | — | EP | disclosed |
| WO-2025151517-A1 | THIAZOLE COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING DISORDERS ASSOCIATED WITH MISSFOLDING OF ALPHA-SYNUCLEIN PROTEIN | WAVEBREAK THERAPEUTICS LIMITED (US) | 2025-07-17 | — | — | WO | disclosed |
| US-6645990-B2 | For prophylaxis and therapy of diseases, such as cell proliferation or apoptosis mediated diseases | AMGEN INC. | 2003-11-11 | — | — | US | disclosed |
| US-20030187266-A1 | Non-nucleoside reverse transcriptase inhibitors | MEDIVIR AB (SE) | 2003-10-02 | — | — | US | disclosed |
| WO-2003070727-A1 | THIAZOLYL UREA COMPOUNDS FOR THE TREATMENT OF CANCER | AMGEN INC. (US) | 2003-08-28 | — | — | WO | disclosed |
| EP-1309589-A2 | UREA COMPOUNDS AND METHODS OF USES | Amgen Inc. (US) | 2003-05-14 | — | — | EP | disclosed |
| US-20030069224-A1 | Non-nucleoside reverse transcriptase inhibitors | MEDIVIR AB (SE) | 2003-04-10 | — | — | US | disclosed |
| US-20020193405-A1 | Thiazolyl urea compounds and methods of uses | AMGEN INC. | 2002-12-19 | — | — | US | disclosed |
| US-20020173507-A1 | Urea compounds and methods of uses | AMGEN INC. | 2002-11-21 | — | — | US | disclosed |
| WO-2002070516-A2 | CYCLOPROPAHETEROCYCLES AS NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | MEDIVIR AB (SE) | 2002-09-12 | — | — | WO | disclosed |
| WO-2002014311-A2 | UREA COMPOUNDS AND METHODS OF USES | AMGEN INC. (US) | 2002-02-21 | — | — | WO | disclosed |